Artemis Medicare Services shareholding pattern

ARTEMISMED

212.8

4.53 (-2.08%)
Last updated on 4 Feb, 2026 | 15:13 IST
alert_iconwatchlist_icon
BUYSELL

alert_iconThe current prices are delayed, login to your account for live prices

Artemis Medicare Services Shareholding Pattern

  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
Total Promoters
Segment
Percent

Total Promoters

67.17%

Mutual Fund

1.74%

Insurance

0.49%

Foreign Institutional Investors

0.65%

Domestic Institutional Investors

9.35%

Retail

20.6%

Others

0%

Total Promoters
MAR '24
68.03%
JUN '24
67.51%
SEP '24
67.17%
DEC '24
67.17%

Summary

For Year 2025-26, Artemis Medicare Services reports the following shareholding: Total Promoters at 58.39%, Mutual Fund at 1.69%, Insurance at 0%, Foreign Institutional Investors at 12.47%, Domestic Institutional Investors at 7.38%, and Retail at 20.08%. This breakdown provides a quick snapshot of ownership distribution for Artemis Medicare Services in 2025-26.

Artemis Medicare Services FAQs

As of 02-2026, the promoter shareholding in Artemis Medicare Services stands at 58.39% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.

The FII and DII shareholding of Artemis Medicare Services is 12.47% and 7.38% respectively.

The retail shareholding of the Artemis Medicare Services is 20.08%.

Changes in shareholding patterns of Artemis Medicare Services can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.

Shareholding patterns of Artemis Medicare Services are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.

The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.